JP2022539256A5 - - Google Patents

Info

Publication number
JP2022539256A5
JP2022539256A5 JP2022500099A JP2022500099A JP2022539256A5 JP 2022539256 A5 JP2022539256 A5 JP 2022539256A5 JP 2022500099 A JP2022500099 A JP 2022500099A JP 2022500099 A JP2022500099 A JP 2022500099A JP 2022539256 A5 JP2022539256 A5 JP 2022539256A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
cancer
haloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500099A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595055B2 (ja
JP2022539256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040299 external-priority patent/WO2021003157A1/en
Publication of JP2022539256A publication Critical patent/JP2022539256A/ja
Publication of JP2022539256A5 publication Critical patent/JP2022539256A5/ja
Application granted granted Critical
Publication of JP7595055B2 publication Critical patent/JP7595055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500099A 2019-07-02 2020-06-30 eIF4E阻害4-オキソ-3,4-ジヒドロピリド[3,4-D]ピリミジン化合物 Active JP7595055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869,662 2019-07-02
PCT/US2020/040299 WO2021003157A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Publications (3)

Publication Number Publication Date
JP2022539256A JP2022539256A (ja) 2022-09-07
JP2022539256A5 true JP2022539256A5 (cg-RX-API-DMAC10.html) 2023-06-16
JP7595055B2 JP7595055B2 (ja) 2024-12-05

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500099A Active JP7595055B2 (ja) 2019-07-02 2020-06-30 eIF4E阻害4-オキソ-3,4-ジヒドロピリド[3,4-D]ピリミジン化合物

Country Status (15)

Country Link
US (2) US11286268B1 (cg-RX-API-DMAC10.html)
EP (1) EP3994139A1 (cg-RX-API-DMAC10.html)
JP (1) JP7595055B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220061945A (cg-RX-API-DMAC10.html)
CN (1) CN114269756B (cg-RX-API-DMAC10.html)
AR (1) AR119339A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020299362B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021026682A2 (cg-RX-API-DMAC10.html)
CA (2) CA3188446A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003573A1 (cg-RX-API-DMAC10.html)
IL (1) IL289456A (cg-RX-API-DMAC10.html)
PY (1) PY2031844A (cg-RX-API-DMAC10.html)
TW (1) TWI748541B (cg-RX-API-DMAC10.html)
UY (1) UY38773A (cg-RX-API-DMAC10.html)
WO (1) WO2021003157A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
KR20230124648A (ko) * 2020-12-22 2023-08-25 화이자 인코포레이티드 Eif4e 억제제의 고체 형태
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
AU2023375677A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9540371B2 (en) 2013-04-29 2017-01-10 Vanderbilt University Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス, インコーポレイテッド 線維性疾患を治療するための方法
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Similar Documents

Publication Publication Date Title
JP2023531269A5 (cg-RX-API-DMAC10.html)
KR950704288A (ko) 7-할로-및 7β,8β-메타노-탁솔, 그를 함유하는 약학 조성물 및 항종양제로서의 그의 용도(7-HALO-AND 7β,8β-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM)
JP2022540890A5 (cg-RX-API-DMAC10.html)
JP2022537773A5 (cg-RX-API-DMAC10.html)
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2023515479A5 (cg-RX-API-DMAC10.html)
US5811452A (en) Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
JP2022529854A5 (cg-RX-API-DMAC10.html)
JP2020506951A5 (cg-RX-API-DMAC10.html)
JP2023509366A5 (cg-RX-API-DMAC10.html)
JP2020189977A5 (cg-RX-API-DMAC10.html)
JP2022549510A5 (cg-RX-API-DMAC10.html)
RU2010116274A (ru) Аналоги азацитидина и их применение
RU2010106878A (ru) Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака
JP2022540333A5 (cg-RX-API-DMAC10.html)
JP2021519785A5 (cg-RX-API-DMAC10.html)
JP2006514960A5 (cg-RX-API-DMAC10.html)
RU2011131985A (ru) Толуидинсульфонамиды и их применение
CA2380022C (en) Aromatic esters of camptothecins and methods to treat cancers
JP2023542065A5 (cg-RX-API-DMAC10.html)
JP2006515858A5 (cg-RX-API-DMAC10.html)
JP2019509986A5 (cg-RX-API-DMAC10.html)
RU2012149452A (ru) Способ усиления антителозависимой клеточной цитотоксичности
JP2021523169A5 (cg-RX-API-DMAC10.html)
US5547981A (en) Taxol-7-carbazates